In this issue:
Long-term survival of combined hepatocellular cholangiocarcinoma
TACE with cisplatin vs. epirubicin for HCC
Treatment-related toxicity and improved outcomes from immunotherapy in HCC
Real-world efficacy and safety of ICIs in advanced HCC
Prognostic score for patients with immunotherapy-treated HCC
Comparisons of risk prediction models for HBV-related HCC
Bridging SBRT for HCC while awaiting liver transplantation
Lenvatinib, anti-PD-1 therapy + TACE for unresectable HCC
Intrahepatic cholangiocarcinoma vs. HCC: clinical features/outcomes
Please login below to download this issue (PDF)